ClinicalTrials.gg
RecruitingNCT06481917SAPHARIUpdated Nov 20, 2026

Home-based Nurse Intervention in the Care of High Risk of Death Patients After Discharge From Geriatric Department

An interventional study of Advance care plan and Ergonomic analysis in Health Services for the Aged and Advance Care Planning, sponsored by Lille Catholic University. Recruiting at 6 sites in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Lille Catholic University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Study summary

This study consists to evaluate the feasibility of a case-management intervention of Advance Care Plan (ACP) placement for elderly patients at high risk of death at twelve months discharged alive from acute geriatric medicine.

Feasibility will include the following indicators: rate of patients included and randomized, rate of patients remaining in the study, ACP rates achieved at one month.

02

Conditions studied

  • Health Services for the Aged
  • Advance Care Planning

Keywords

  • Elderly
  • Advance care plan
  • DAMAGE score
  • High risk of mortality
  • Discharge from acute care geriatric department
03

In context

Lead sponsor

Lille Catholic University is the lead sponsor of 112 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 75 or over.
  • Affiliated to a social security scheme.
  • Hospitalized in an acute care geriatric department
  • Discharged from hospital to home or residential facilities for dependent elderly people
  • Targeted pathology or at least one incurable disease.
  • At high risk of death in the twelve months following discharge according to the DAMAGE prognostic score (high-risk score group). A high risk of death is defined by a DAMAGE score > 50%.
  • Rockwood Clinical frailty scale score greater than or equal to 7 at one month.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study expressed by the patient or his/her legal representative, if applicable.
  • Patients transferred to another Medicine-Surgery-Obstetrics department (only "medicine or surgery" in the elderly).
  • Patients transferred to follow-up care and rehabilitation, palliative care, or returning home in palliative care.
  • Patients who have already drawn up advance directives, chosen a trusted support person or discussed their end-of-life wishes with their doctor.
  • Patients with proven severe neuro-cognitive disorders (in the medical record with a (MMSE) score below 10 or in the absence of knowledge of the degree of severity and/or a recent previous MMSE score taken in a stable period, the referring practitioner, a geriatrician with expertise in this field, will assess whether the patient is unfit to state his or her advance directives at the time of inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Advance care plan

    Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.

    Other: Advance care plan · Other: Ergonomic analysis · Other: Evaluation of intervention acceptability

  • No intervention
    Usual care

    Usual care with the possibility of proposing ACP according to the department's habits

Interventions

  • OtherAdvance care plan

    Scheduling of 2 home visits by an expert nurse in the month following the return home and proposal to carry out an advance care plan.

  • OtherErgonomic analysis

    Ergonomic analysis throughout the intervention

  • OtherEvaluation of intervention acceptability

    Evaluation of intervention acceptability after each home visit with patients and caregivers using a questionnaire

06

What researchers measure

Primary outcomes

  1. Rate of included patients

    Time frame: 12 months

  2. Rate of patients remaining in the study

    Time frame: 12 months

  3. Advance care planning rate achieved

    Time frame: 12 months

Secondary outcomes

  1. Rate of compliance to advance directives

    Rate of compliance with the patient's advance directives one year after discharge from hospital; compliance to the the following situations will be identified: * The patient is still alive: wishes to be re-hospitalized / does not wish to be re-hospitalized / has not made a decision. * The patient is deceased: place of death specified: hospital, home or other / no decision taken.

    Time frame: 12 months

  2. Hospital Anxiety and Depression Scale (HADS) of caregivers and carers

    Anxiety-depressive symptomatology of caregivers will be assessed using the Hospital Anxiety and Depression Scale (HADS) in the event of patient death, if this occurs within one year of discharge from hospital. The HAD scale is a screening instrument for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven to depression (total D), giving two scores (maximum score for each = 21). To screen for anxiety and depressive symptoms, the following interpretation can be proposed for each of the scores (A and D) each of the scores (A and D): * 7 or less: no symptoms * 8 to 10: doubtful symptomatology - 11 or more: definite symptomatology.

    Time frame: 12 months

  3. Questionnaire to evaluate the acceptability of the intervention

    The acceptability of the intervention will be assessed by a questionnaire after each home visit at 7 days and one month, with patients and caregivers in the intervention group.

    Time frame: 12 months

  4. EQ-5D-3L scale score

    Changes in the quality of life of patients and caregivers one month after hospital discharge will be measured by changes in the EQ-5D-3L scale score. EQ-5D is a standardised measure of health-related quality of life.n EQ-5D-3L, the five dimensions each have three response levels of severity. Respondents are asked to choose the statement in each dimension that best describes their health status on the day they are surveyed. Their responses are coded as a number (1, 2, or 3) that corresponds to the respective level of severity: 1 indicates no problems, 2 some problems, and 3 extreme problems. In this way, a person's health state profile can be defined by a 5-digit number, ranging from 11111 (having no problems in any of the dimensions) to 33333 (having extreme problems in all the dimensions).

    Time frame: 12 months

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2025 (actual). Primary completion is estimated for May 2027, 28 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Oct 2024 → Jan 2025, primary completion May 2026 → May 2027 and completion Oct 2027 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 1, 2024
StartActual
Jan 14, 2025was Oct 2024
Primary completionEst.
May 2027was May 2026
CompletionEst.
Oct 2029was Oct 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
Show 6 sites
  • CHU d'Amiens · Amiens, Franceno status→Not yet recruiting
  • CHU de Caen · Caen, Franceno status→Not yet recruiting
  • CHU de Lille · Lille, Franceno status→Not yet recruiting
  • Hôpital Saint Vincent de Paul (GHICL) · Lille, Franceno status→Not yet recruiting
  • Hôpital Saint-Philibert (GHICL) · Lomme, Franceno status→Recruiting
  • CHU de Rouen · Rouen, Franceno status→Not yet recruiting
Nov 20, 2026
Start date
Oct 2024→Jan 14, 2025 (actual)
Nov 20, 2026
Primary completion
May 2026→May 2027
Nov 20, 2026
Study completion
Oct 2027→Oct 2029
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
    Show 6 sites
    • CHU d'Amiens · Amiens, Franceno status→Not yet recruiting
    • CHU de Caen · Caen, Franceno status→Not yet recruiting
    • CHU de Lille · Lille, Franceno status→Not yet recruiting
    • Hôpital Saint Vincent de Paul (GHICL) · Lille, Franceno status→Not yet recruiting
    • Hôpital Saint-Philibert (GHICL) · Lomme, Franceno status→Recruiting
    • CHU de Rouen · Rouen, Franceno status→Not yet recruiting
    Start date Oct 2024→Jan 14, 2025 (now actual)
    Primary completion May 2026→May 2027
    Study completion Oct 2027→Oct 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06481917
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jan 14, 2025
Primary completion
May 2027 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Marie Paule LEBITASY
Contact
urm@ghicl.net
+33 3 20 22 52 69
William's VAN DEN BERGHE
Contact
VanDenBerghe.Williams@ghicl.net
+33320225731
Fabien VISADE
principal investigator · Hôpital Saint Philibert, GHICL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion